Search

Your search keyword '"Flori, Maria"' showing total 6 results
Start Over Author "Flori, Maria" Topic psoriasis
6 results on '"Flori, Maria"'

1. Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study.

Author

Galluzzo M, Talamonti M, Atzori L, Bardazzi F, Campanati A, Di Cesare A, Diotallevi F, Flori ML, Mugheddu C, Offidani A, Piaserico S, Russo F, Sacchelli L, Bianchi L, and Prignano F

Subjects
Humans, Retrospective Studies, Severity of Illness Index, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Psoriasis drug therapy
Abstract

Background: Palmoplantar psoriasis is difficult to treat and often recalcitrant to conventional therapies. Clinical trials have demonstrated the efficacy and safety of secukinumab for this debilitating psoriasis form, but real-life evidence is currently limited. Therefore, here we described the outcomes of patients treated with secukinumab in clinical practice., Research Design and Methods: This was a real-life, retrospective, observational study involving patients with palmoplantar psoriasis treated with secukinumab (300 mg, subcutaneously) at seven dermatologic clinics in Italy. Treatment effectiveness was evaluated based on the changes of the Psoriasis Area and Severity Index (PASI) and palmoplantar (pp) PASI during treatment and by recording safety and tolerability issues over 104 weeks., Results: Forty-three patients initiated treatment with secukinumab. Previous treatments included topical and systemic therapies; half of patients had already tried one or more biologics. Secukinumab improved mean PASI rapidly and substantially with a 78.2% decrease at 16 weeks. Mean ppPASI also improved substantially, but more gradually, with reductions of 55.0% and 79.3% at 16 and 104 weeks, respectively. Approximately half of patients achieved complete skin clearance at 40 weeks. Secukinumab was well tolerated and no relevant treatment-related adverse events were reported., Conclusions: Secukinumab appears to be effective for the treatment of palmoplantar psoriasis also in the real-life setting.

Published
2022
Full Text
View/download PDF

3. Cyclosporine in psoriasis: comparison of a 25-year real-world Italian experience to current European guidelines.

Author

Altomare G, Ayala F, Bardazzi F, Bellia G, Chimenti S, Colombo D, Flori ML, Girolomoni G, Micali G, Parodi A, Peris K, and Vena GA

Subjects
Adult, Child, Dermatitis, Atopic drug therapy, Dermatitis, Atopic pathology, Europe, Humans, Immunosuppressive Agents therapeutic use, Italy, Practice Guidelines as Topic, Psoriasis pathology, Cyclosporine therapeutic use, Dermatologic Agents therapeutic use, Psoriasis drug therapy
Abstract

Cyclosporine (CsA) is an effective and safe therapeutic option in various dermatoses in both adults and children. Over the last 25 years, Italian dermatologists have gained relevant experience about the use of CsA in the treatment of psoriasis and atopic dermatitis, and an Italian Consensus Conference has recently provided recommendations in adult patients. A comparison between these real-world indications and current European guidelines is hereby provided.

Published
2016

4. The GENDER ATTENTION Observational Study: Gender and Hormonal Status Differences in the Incidence of Adverse Events During Cyclosporine Treatment in Psoriatic Patients

Author

Colombo, Delia, Banfi, Giuseppe, Cassano, Nicoletta, Graziottin, Alessandra, Vena, Gino Antonio, Fiori, Giovanni Gualberto, Zagni, Emanuela, Stingeni, Luca, Chimenti, Sergio, Berardesca, Enzo, Micali, Giuseppe, Albertini, Giuseppe, De Simone, Clara, Bellia, Gilberto, Amato, Salvatore, Ayala, Fabio, Bardazzi, Ferderico, Bernengo, Maria Grazia, Bongiorno, Maria Rita, Borroni, Giovanni, Calvieri, Stefano, Pinton, Piergiacomo Calzavara, Cannarozzo, Calcedonio, Cannavò, Serafinella Patrizia, Cattaneo, Angelo, Ceschini, Rossella, Colombo, Enrico, Congedo, Maurizio, Cusano, Francesco, De Pità, Ornella, Di Nuzzo, Sergio, Donadio, Dario, Donelli, Stefano, Filotico, Raffaele, Flori, Maria Laura, Germino, Maurizio, Girolomoni, Giampiero, Kokelj, Franco, Lanzoni, Anna, Lembo, Giuseppe, Locatelli, Andrea, Magnoni, Cristina, Marconi, Marco, Motolese, Alberico, Papini, Manuela, Parodi, Aurora, Pau, Monica, Peris, Ketty, Piaserico, Stefano, Piccirillo, Angelo, Potenza, Concetta, Ricotti, Giuseppe, Sedona, Patrizio, Stinco, Giuseppe, Valenti, Giancarlo, Fornasa, Cleto Veller, Zichichi, Leonardo, Ori, Alessandra, Amici, Christian, Zullo, Alessandro, Simoni, Lucia, Lanci, Nicole, Longagnani, Chiara, Sala, Saide, Trevisan, Francesca, Magri, Giovanna, and On behalf of the GENDER ATTENTION study group

Published
2017
Full Text
View/download PDF

5. Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

Author

Luca Stingeni, Andrea Chiricozzi, Piergiorgio Malagoli, Anna Campanati, Marina Venturini, Antonio Costanzo, Anna Balato, Paolo Gisondi, Clara De Simone, Giampiero Girolomoni, Maria Letizia Musumeci, Aurora Parodi, Franco Rongioletti, Angelo Cattaneo, Claudia Lasagni, Santo Raffaele Mercuri, Valentina Dini, Francesca Prignano, Federico Bardazzi, Concetta Potenza, Claudio Guarneri, Ada Lo Schiavo, Ketty Peris, A. M. Offidani, Manuela Papini, Paolo Dapavo, Francesco Loconsole, Maria Laura Flori, Francesco Cusano, Maria Concetta Fargnoli, Stefano Piaserico, Marco Galluzzo, Paolo Amerio, Piergiacomo Calzavara Pinton, Luca Bianchi, Marina Talamonti, Luigi Naldi, Rossana Tiberio, G. Malara, Gisondi, Paolo, Talamonti, Marina, Chiricozzi, Andrea, Piaserico, Stefano, Amerio, Paolo, Balato, Anna, Bardazzi, Federico, Calzavara Pinton, Piergiacomo, Campanati, Anna, Cattaneo, Angelo, Dapavo, Paolo, De Simone, Clara, Dini, Valentina, Fargnoli, Maria C, Flori, Maria L, Galluzzo, Marco, Guarneri, Claudio, Lasagni, Claudia, Loconsole, Francesco, Lo Schiavo, Ada, Malagoli, Piergiorgio, Malara, Giovanna, Mercuri, Santo R, Musumeci, Maria L, Naldi, Luigi, Papini, Manuela, Parodi, Aurora, Potenza, Concetta, Prignano, Francesca, Rongioletti, Franco, Stingeni, Luca, Tiberio, Rossana, Venturini, Marina, Bianchi, Luca, Costanzo, Antonio, Cusano, Francesco, Girolomoni, Giampiero, Offidani, Anna M, Peris, Ketty, Gisondi, P., Talamonti, M., Chiricozzi, A., Piaserico, S., Amerio, P., Balato, A., Bardazzi, F., Calzavara Pinton, P., Campanati, A., Cattaneo, A., Dapavo, P., De Simone, C., Dini, V., Fargnoli, M. C., Flori, M. L., Galluzzo, M., Guarneri, C., Lasagni, C., Loconsole, F., Lo Schiavo, A., Malagoli, P., Malara, G., Mercuri, S. R., Musumeci, M. L., Naldi, L., Papini, M., Parodi, A., Potenza, C., Prignano, F., Rongioletti, F., Stingeni, L., Tiberio, R., Venturini, M., Bianchi, L., Costanzo, A., Cusano, F., Girolomoni, G., Offidani, A. M., and Peris, K.

Subjects
Quality of life, Moderate to severe, medicine.medical_specialty, Consensus, Delphi method, Consensu, Dermatology, Plaque psoriasis, Systemic inflammation, Treat-to-target, 030207 dermatology & venereal diseases, 03 medical and health sciences, Settore MED/35, 0302 clinical medicine, Quality of life (healthcare), Psoriasis Area and Severity Index, Psoriasis, consensus, plaque psoriasis, quality of life, systemic inflammation, treatto-target, medicine, Intensive care medicine, Original Research, business.industry, Treat to target, Dermatology Life Quality Index, medicine.disease, Plaque psoriasi, 030220 oncology & carcinogenesis, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business
Abstract

Introduction: Treat-to-target strategies are used in several chronic diseases to improve outcomes. Treatment goals have also been suggested for psoriasis, but there is currently no consensus on targets, and guidance is needed to implement this strategy in clinical practice. The project ‘Treat to Target Italia’ was launched by a scientific board (SB) of 10 psoriasis experts to generate expert consensus recommendations. Methods: On the basis of the published literature, their clinical experience, and the results of a survey among Italian dermatologists, the SB identified four relevant topics: (1) clinical remission; (2) quality of life; (3) abrogation of systemic inflammation; (4) safety. They drafted 20 statements addressing these four topics and submitted them to a panel of 28 dermatologists, in a Delphi process, to achieve consensus (greater than 80% agreement). Results: Consensus was reached on all statements. Treatment goals defining clinical remission should include a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI90 response) or an absolute PASI score of less than or equal to 3. Patient’s quality of life and satisfaction are important targets. If PASI targets are achieved, there should be no or very low impact of psoriasis on quality of life [Dermatology Life Quality Index (DLQI) score less than or equal to 3]. If PASI or DLQI goals are not achieved within 3–4months, treatment should be changed. Abrogation of systemic inflammation may be crucial for preventing or delaying inflammatory comorbidities. Safety is an equally important target as efficacy. Conclusion: These 20 consensus statements define the parameters of a treat-to-target strategy for psoriasis in Italy. It is hoped that use of these in the management of patients with psoriasis will improve treatment outcomes and patient health-related quality of life.

Published
2021

6. Cyclosporine in psoriasis: comparison of a 25-year real-world Italian experience to current European guidelines

Author

Altomare, G., Ayala, F., Bardazzi, F., Bellia, G., Chimenti, S., Colombo, D., Flori, M. L., Girolomoni, G., Giuseppe MICALI, Parodi, A., Peris, K., Vena, G. A., Altomare, Gianfranco, Ayala, Fabio, Bardazzi, Federico, Bellia, Gilberto, Chimenti, Sergio, Colombo, Delia, Flori, Maria L, Girolomoni, Giampiero, Micali, Giuseppe, Parodi, Aurora, Peris, Ketty, and Vena, Gino A.

Subjects
Adult, Europe, Skin diseases, Italy, Practice Guidelines as Topic, Cyclosporine, Psoriasis, Humans, Dermatologic Agents, Child, Immunosuppressive Agents, Dermatitis, Atopic
Abstract

Cyclosporine (CsA) is an effective and safe therapeutic option in various dermatoses in both adults and children. Over the last 25 years, Italian dermatologists have gained relevant experience about the use of CsA in the treatment of psoriasis and atopic dermatitis, and an Italian Consensus Conference has recently provided recommendations in adult patients. A comparison between these real-world indications and current European guidelines is hereby provided.

Catalog

Books, media, physical & digital resources
See catalog results